SuperworthJohnson & Johnson profit margin JNJ
Gross, operating and net profit as a share of revenue over the last twelve months, from 2009.
- Net margin, 12 months
- n/m
- not a meaningful number
- Operating margin, 12 months
- 26.5%
- Net margin on a year earlier
- −3.5 pts
- Peer median
- 9.8%
Johnson & Johnson's net margin works out at 21% over the last twelve months, but it is not a meaningful number: net income for Q3 FY26 is missing, so twelve months can't be added up yet.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 28.5% | 26.8% | 67.9% |
| FY2024 | 15.8% | 23.4% | 69.1% |
| FY2023 | 41.3% | 24.9% | 68.8% |
| FY2022 | 22.4% | 24.2% | 69.3% |
| FY2021 | 22.3% | 24.9% | 68.2% |
| FY2020 | 17.8% | 23.6% | 65.6% |
| FY2019 | 18.4% | 24.1% | 66.4% |
| FY2018 | 18.8% | 22.3% | 66.8% |
| FY2017 | 1.7% | 23.6% | 66.7% |
| FY2016 | 23.0% | 28.7% | 69.8% |
| FY2015 | 22.0% | 25.1% | 69.3% |
| FY2014 | 22.0% | 28.2% | 69.4% |
| FY2013 | 19.4% | 25.8% | 68.7% |
| FY2012 | 16.1% | 23.6% | 67.8% |
| FY2011 | 14.9% | 24.0% | 68.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 21.5% | −3.5 pts | 26.5% | |
| Q1 FY26 | 21.8% | −2.6 pts | 26.4% | |
| Q4 FY25 | 28.5% | +12.6 pts | 26.8% | |
| Q3 FY25 | 27.3% | +10.5 pts | 25.4% | |
| Q2 FY25 | 25.0% | −18.9 pts | 23.7% | |
| Q1 FY25 | 24.4% | −20.5 pts | 23.6% | |
| Q4 FY24 | 15.8% | −25.4 pts | 23.4% | |
| Q3 FY24 | 16.7% | −24.6 pts | 24.4% | |
| Q2 FY24 | 43.9% | +28.1 pts | 25.3% | |
| Q1 FY24 | 44.9% | +29.2 pts | 25.0% | |
| Q4 FY23 | 41.3% | +18.9 pts | 24.9% | |
| Q3 FY23 | 41.4% | +18.8 pts | 24.9% |
Against its peers
Companies in Drug Manufacturers - General nearest Johnson & Johnson's size, closest first, today.
| Company | Profit margin |
|---|---|
| JNJJohnson & Johnson | n/m |
| ABBVAbbVie | 9.8% |
| MRKMerck | 4.8% |
| LLYEli Lilly and | 33.5% |
| AMGNAmgen | 23.0% |
| GILDGilead Sciences | −10.6% |
| PFEPfizer | 6.8% |
| BMYBristol-Myers Squibb | 18.9% |
| Peer median | 9.8% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Johnson & Johnson
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.